Literature DB >> 20383820

Correlation of circulating endoglin with clinical outcome in biliary atresia.

K Preativatanyou1, S Honsawek, V Chongsrisawat, P Vejchapipat, A Theamboonlers, Y Poovorawan.   

Abstract

BACKGROUND AND AIM: Biliary atresia (BA) is a chronic progressive inflammatory disorder of the extrahepatic and intrahepatic biliary system in children. The aim of the present study was to investigate circulating endoglin levels in BA patients compared with healthy controls and to determine the relationship between plasma endoglin levels and outcome parameters of BA patients after Kasai operation.
METHODS: Fifty-five postoperative BA patients and 14 healthy controls were recruited. The patients were divided into two groups based on their serum total bilirubin levels (TB<34.2, no jaundice vs. TB>or=34.2 micromol/L, persistent jaundice) and serum alanine aminotransferase (ALT<45, normal ALT vs. ALT>or=45 IU/L, high ALT). Circulating endoglin levels were analyzed by enzyme-linked immunosorbent assay.
RESULTS: Average levels of plasma endoglin were significantly higher in BA patients compared to healthy controls (7.8+/-0.4 vs. 6.5+/-0.4 ng/mL; P=0.02). BA patients with persistent jaundice had higher plasma endoglin levels than those without jaundice (9.2+/-0.8 vs. 6.9+/-0.3 ng/mL; P=0.006). Furthermore, the concentrations of plasma endoglin in BA patients with high ALT were significantly higher compared to those with normal ALT (8.5+/-0.5 vs. 6.3+/-0.5 ng/mL, P=0.003). In addition, BA patients with portal hypertension had more elevated plasma endoglin levels than those without portal hypertension (8.8+/-0.6 vs. 6.1+/-0.3 ng/mL, P=0.001). Plasma endoglin was positively correlated with serum ALT (r=0.36, P=0.007) and serum GGT (r=0.44, P=0.001).
CONCLUSION: High circulating endoglin correlated with a poor outcome for BA. Plasma endoglin can be utilized as a potential biomarker reflecting the severity of ongoing liver injury and biliary obstruction in BA patients after Kasai procedure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383820     DOI: 10.1055/s-0030-1249695

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  5 in total

1.  Endoglin in liver fibrosis.

Authors:  Kenneth W Finnson; Anie Philip
Journal:  J Cell Commun Signal       Date:  2011-12-01       Impact factor: 5.782

Review 2.  Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.

Authors:  Steffen K Meurer; Muhammad Alsamman; David Scholten; Ralf Weiskirchen
Journal:  World J Biol Chem       Date:  2014-05-26

Review 3.  Potential roles of BMP9 in liver fibrosis.

Authors:  Jianjun Bi; Shengfang Ge
Journal:  Int J Mol Sci       Date:  2014-11-11       Impact factor: 5.923

4.  Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver.

Authors:  Ivone Cristina Igreja Sá; Katarina Tripska; Milos Hroch; Radomir Hyspler; Alena Ticha; Hana Lastuvkova; Jolana Schreiberova; Eva Dolezelova; Samira Eissazadeh; Barbora Vitverova; Iveta Najmanova; Martina Vasinova; Miguel Pericacho; Stanislav Micuda; Petr Nachtigal
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

5.  Biomarkers for the diagnosis and post-Kasai portoenterostomy prognosis of biliary atresia: a systematic review and meta-analysis.

Authors:  Lin He; Dennis Kai Ming Ip; Greta Tam; Vincent Chi Hang Lui; Paul Kwong Hang Tam; Patrick Ho Yu Chung
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.